Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: Results from the Women's Health Initiative Hormone Trial

Diabetologia

Volumn 47, Issue 7, 2004, Pages 1175-1187

  Margolis, K L ^a,i   Bonds, D E ^b   Rodabough, R J ^c   Tinker, L ^c   Phillips, L S ^d   Allen, C ^e   Bassford, T ^f   Burke, G ^b   Torrens, J ^g   Howard, B V ^h  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^h HOWARD UNIVERSITY   (United States)

ⁱ Berman Center for Outcomes and Clinical Research   (United States)

Author keywords

Diabetes mellitus; Double blind method; Oestrogens; Postmenopause; Progestins; Random allocation

Indexed keywords

ANTIDIABETIC AGENT; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; GLUCOSE; INSULIN; LIPOPROTEIN;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD ASSESSMENT; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MORBIDITY; POSTMENOPAUSE; PRIORITY JOURNAL; SELF REPORT; SENSITIVITY ANALYSIS;

EID: 4143116880     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1448-x     Document Type: Article

References (61)

1. Mokdad A, Ford E, Bowman B et al. (2003) Prevalence of obesity, diabetes and obesity-related health risk factors, 2001. JAMA 289:76-79
2. Espeland M, Hogan P, Fineberg S et al. (1998) Effect of postmenopausal hormone therapy on glucose and insulin concentrations. Diabetes Care 21:1589-1595
3. Writing group for the PEPI Trial (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273:199-208
4. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P, Melis GB (1992) Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 74:1396-1400
5. Lobo R, Pickar J, Wild R, Walsh B, Hirvonen E (1994) Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 84:987-995
6. Cagnacci A, Tuveri F, Cirillo R, Setteneri AM, Melis GB, Volpe A (1997) The effect of transdermal 17-beta-estradiol on glucose metabolism of postmenopausal women is evident during the oral but not the intravenous glucose administration. Maturitas 28:163-167
7. Colacurci N, Zarcone R, Mollo A et al. (1998) Effects of hormone replacement therapy on glucose metabolism. Panminerva Medica 40:18-21
8. Davidson M, Maki K, Marx P et al. (2000) Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 160:3315-3325
9. Hodis H, Mack W, Lobo R et al. (2001) Estrogen in the prevention of atherosclerosis. Ann Intern Med 135:939-953
10. Lobo R, Bush T, Carr B, Pickar J (2001) Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 76:13-24
11. Goldman J, Ovadia J (1969) The effect of estrogen on intravenous glucose tolerance in women. Am J Obstet Gynecol 103:172-178
12. Spellacy W, Buhi W, Birk S (1972) The effect of estrogen on carbohydrate metabolism: glucose, insulin, and growth hormone studies on one hundred and seventy-one women ingesting Premarin, mestranol, and ethinyl estradiol for six months. Am J Obstet Gynecol 114:378-392
13. Ajabor L, Tsai C, Vela P, Yen S (1972) Effect of exogenous estrogen on carbohydrate metabolism in postmenopausal women. Am J Obstet Gynecol 113:383-387
14. De Cleyn K, Buytaert P, Coppens M (1989) Carbohydrate metabolism during hormonal substitution therapy. Maturitas 11:235-242
15. Godsland I, Gangar K, Walton C et al. (1993) Insulin resistance, secretion, and elimination in postmenopausal women receiving oral and transdermal hormone replacement therapy. Metabolism 42:846-853
16. O'Sullivan A, Ho K (1995) A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 80:1783-1788
17. Kimmerle R, Heinemann L, Heise T et al. (1999) Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal non-diabetic women. Menopause 6:36-42
18. Roo G, Stehouwer C, Meijer P et al. (1999) Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 19:2993-3000
19. Seed M, Sands R, McLaren M, Kirk G, Darko D (2000) The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women. Fam Pract 17:497-507
20. Vehkavaara S, Westerbacka J, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Yki-Jarvinen H (2000) Effect of estrogen replacement therapy on insulin sensitivity of glucose metabolism and preresistance and resistance vessel function in healthy postmenopausal women. J Clin Endocrinol Metab 85:4663-4670
21. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT (1979) Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol 133:525-536
22. Gabal L, Goodman-Gruen D, Barrett-Connor E (1997) The effect of postmenopausal estrogen therapy on the risk of non-insulin-dependent diabetes mellitus. Am J Pub Health 87:443-145
23. Zhang Y, Howard B, Cowan L et al. (2002) The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in American Indian postmenopausal women: the Strong Heart Study. Diabetes Care 25:500-504
24. Rossi R, Origlinani G, Modena M (2004) Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care 27:645-649
25. Manson J, Rimm E, Colditz G et al. (1992) A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin- dependent diabetes mellitus. Ann Epidemiol 2:665-673
26. Kanaya A, Herrington D, Vittinghoff E et al. (2003) Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 138:1-9
27. Women's Health Initiative Study Group (1998) Design of the Women's Health Initiative Clinical Trial and Observational Study. Control Clin Trials 19:61-109
28. Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
29. Block G, Woods M, Potosky A, Clifford C (1990) Validation of a self-administered diet history questionnaire using multiple diet records. J Clin Epidemiol 43:1327-1335
30. Patterson R, Kristal A, Coates R et al. (1996) Low-fat diet practices of older women: prevalence and implications for dietary assessment. J Am Diet Assoc 96:670-679
31. Ainsworth B, Haskell W, Leon A et al. (1993) Compendium of physical activities: Classification of energy costs of human physical activities. Med Sci Sports Exerc 25:71-80
32. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R (1985) Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
33. Nabulsi A, Folsom A, White A et al. (1993) Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 328:1069-1075
34. Troisi R, Cowie C, Harris M (2000) Hormone replacement therapy and glucose metabolism. Obstet Gynecol 96:665-670
35. Barrett-Connor E, Laakso M (1990) Ischemic heart disease risk in postmenopausal women: effects of estrogen use on glucose and insulin levels. Arteriosclerosis 10:531-534
36. Cucinelli F, Paparella P, Soranna L et al. (1999) Differential effect of transdermal estrogen plus progestagen replacement therapy on insulin metabolism in postmenopausal women: relation to their insulinemic secretion. Eur J Endocrinol 140:215-223
37. Lindheim SR, Presser SC, Ditkoff EC, Vijod MA, Stanczyk FZ, Lobo RA (1993) A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 60:664-667
38. Sites C, Brochu M, Tchernof A, Poehlman E (2001) Relationship between hormone replacement therapy use with body fat distribution and insulin sensitivity in obese postmenopausal women. Metabolism 50:835-840
39. Ryan A, Nicklas B, Berman D (2002) Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care 25:127-133
40. Roussel A-M, Bureau I, Favier M, Polansky M, Bryden N, Anderson R (2002) Beneficial effects of hormone replacement therapy on chromium status and glucose and lipid metabolism in postmenopausal women. Maturitas 42:63-69
41. Evans E, Van Pelt E, Binder E, Williams D, Ehsani A, Kohrt W (2001) Effects of HRT and exercise training on insulin action, glucose tolerance, and body composition in older women. J Appl Physiol 90:2033-2040
42. Duncan A, Lyall H, Roberts R et al. (1999) The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women. J Clin Endocrinol Metab 84:2402-2407
43. Crook D, Godsland I, Hull J, Stevenson J (1997) Hormone replacement therapy with dydrogesterone and 17 beta-oestradiol: effects on serum lipoproteins and glucose tolerance during 24 month follow up. Br J Obstet Gynaecol 104:298-304
44. Walker RJ, Lewis-Earned NJ, Sutherland WH et al. (2001) The effects of sequential combined oral 17 beta-estradiol norethisterone acetate on insulin sensitivity and body composition in healthy postmenopausal women: a randomized single blind placebo-controlled study. Menopause 8:27-32
45. Fonseca E, Ochoa R, Galvan R, Hernandez M, Mercado M, Zarate A (1999) Increased serum levels of growth hormone and insulin-like growth factor-I associated with simultaneous decrease of circulating insulin in postmenopausal women receiving hormone replacement therapy. Menopause 6:56-60
46. Wilcox JG, Hwang J, Hodis HN, Sevanian A, Stanczyk FZ, Lobo RA (1997) Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertil Steril 67:57-62
47. Livingstone C, Collison M (2002) Sex steroids and insulin resistance. Clin Sci (Lond) 102:151-166
48. Oh J-Y, Barrett-Connor E, Wedick N, Wingard D (2002) Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo Study. Diabetes Care 25:55-60
49. Kalish G, Barrett-Connor E, Laughlin G, Gulanski B (2003) Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial. J Clin Endocrinol Metab 88:1646-1652
50. Haffner S, Dunn J, Katz MS (1992) Relationship of sex-hormone-blinding globulin to lipid, lipoprotein, glucose and insulin concentrations in postmenopausal women. Metabolism 41:278-284
51. Lindstedt G, Lundberg P-A, Lapidus L, Lundgren H, Bengtsson B, Björntorp P (1991) Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. Diabetes 40:123-128
52. Haffner S, Valdez R, Morales P, Hazuda H, Stern M (1993) Decreased sex-hormone-binding globulin predicts non-insulin-dependent diabetes mellitus in women but not in men. J Clin Endocrinol Metab 77:56-60
53. Andersson B, Mattsson L, Hahn L et al. (1997) Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:638-643
54. Kaye S, Folsom A, Sprafka J, Prineas R, Wallace R (1991) Increased incidence of diabetes mellitus in relation to abdominal adiposity in older women. J Clin Epidemiol 44:329-334
55. Kehoe R, Wu S-Y, Leske M, Chylack L (1994) Comparing self-reported and physician-reported medical history. Am J Epidemiol 139:813-818
56. Midthjell K, Holmen J, Bjorndal A, Lund-Larsen P (1992) Is questionnaire information valid in the study of a chronic disease such as diabetes? The Nord-Trondelag diabetes study. J Epidemiol Community Health 46:537-542
57. Tretli S, Lund-Larsen P, Foss O (1982) Reliability of questionnaire information on cardiovascular disease and diabetes: cardiovascular disease study in Finnmark county. J Epidemiol Community Health 36:269-273
58. Kriegsman D, Penninx B, Eijk J van, Boeke A, Deeg D (1996) Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly: a study on the accuracy of patients' self-reports and on determinants of inaccuracy. J Clin Epidemiol 49:1407-1417
59. Harris M, Flegal K, Cowie C et al. (1998) Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Study, 1988-1994. Diabetes Care 21:518-524
60. The Women's Health Initiative Steering Committee (2004) Effects of conjugated equine estrogens in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712
61. Kim C, Seidel K, Begier E, Kwok Y (2001) Diabetes and depot medroxyprogesterone contraception in Navajo women. Arch Intern Med 161:1766-1771